EH3A Stock Overview
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Amarin Corporation plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.78 |
| 52 Week High | US$1.26 |
| 52 Week Low | US$0.56 |
| Beta | 2.01 |
| 1 Month Change | 6.16% |
| 3 Month Change | -30.80% |
| 1 Year Change | -28.90% |
| 3 Year Change | -81.41% |
| 5 Year Change | -95.39% |
| Change since IPO | -63.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| EH3A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.5% | -3.1% | 1.8% |
| 1Y | -28.9% | -22.4% | 2.2% |
Return vs Industry: EH3A underperformed the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: EH3A underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| EH3A volatility | |
|---|---|
| EH3A Average Weekly Movement | 13.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EH3A's share price has been volatile over the past 3 months.
Volatility Over Time: EH3A's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 275 | Pat Holt | www.amarincorp.com |
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers.
Amarin Corporation plc Fundamentals Summary
| EH3A fundamental statistics | |
|---|---|
| Market cap | €338.88m |
| Earnings (TTM) | -€55.22m |
| Revenue (TTM) | €286.72m |
1.2x
P/S Ratio-6.1x
P/E RatioIs EH3A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EH3A income statement (TTM) | |
|---|---|
| Revenue | US$306.91m |
| Cost of Revenue | US$102.14m |
| Gross Profit | US$204.77m |
| Other Expenses | US$263.88m |
| Earnings | -US$59.11m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 01, 2024
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 66.72% |
| Net Profit Margin | -19.26% |
| Debt/Equity Ratio | 0% |
How did EH3A perform over the long term?
See historical performance and comparison